Evaluation of miR-130b-3p and miR-375 levels and telomere length with telomerase activity in prostate cancer

MakaleAçık ErişimScopus SJRQ3
  • SDG 3 · Sağlık ve Kaliteli Yaşam

Özet

Prostate cancer (PC) is the most frequent cancer in males, as well as the second highest cause of cancer-related deaths in men. Differences in expression levels of miRNAs were linked with prostat cancer pathogenesis. qPCR was used to evaluate the expression of miR-130b-3p and miR-375 in Benign Prostate Hyperplasia (BPH (n = 20) and PC (n = 22, pre- and post-operative) patients plasma. Relative telomere lengths (RLTs) in genomic DNA isolated from plasma were measured with qPCR, and telomerase activity analyzed by the ELISA method. PSA levels of PC patients were greater than of BPH patients (p = 0.0473). miR-130b-3p and miR-375 levels were significantly lower in pre-operative specimens of PC patients according to BPH (p = 0,0362, p = 0.0168, respectively). Similarly, post-operative miR-375 levels were lower in PC patients than in BPH patients (p = 0.1866). BPH patients had shorter RTLs than PC patients in both pre- (p=0.0438) and post-operative (p=0.0297) specimens. Telomerase activity was higher in PC patients than BPH(p = 0.0129). Interestingly, telomerase activity was further increased after surgery (p = 0.0003). We aim to identify the levels of miR-130b-3p and miR-375 expression and their relationship with telomerase activity in PC patients. Our data suggest that miRNAs and telomere length (TL) with telomerase activity may play a role in regulating prostate tumorgenesis and may be used as biomarkers for PC diagnosis.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/bayburt/11539Resmi atıflarda kullanılan kalıcı adres
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
Scopus
0
WoS
0
OpenAlex
0
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKaradağ, Abdullah
dc.contributor.authorDirican, Ebubekir
dc.contributor.authorÖzmerdiven, Çağdaş Gökhun
dc.contributor.authorÖzen, Ata
dc.contributor.authorAyan, Semih
dc.contributor.authorKabadere, Selda
dc.date.accessioned2026-10-29T19:08:30.635060524Z
dc.date.available2026-10-29T19:08:30.635060524Z
dc.date.issued2025
dc.description.abstractProstate cancer (PC) is the most frequent cancer in males, as well as the second highest cause of cancer-related deaths in men. Differences in expression levels of miRNAs were linked with prostat cancer pathogenesis. qPCR was used to evaluate the expression of miR-130b-3p and miR-375 in Benign Prostate Hyperplasia (BPH (n = 20) and PC (n = 22, pre- and post-operative) patients plasma. Relative telomere lengths (RLTs) in genomic DNA isolated from plasma were measured with qPCR, and telomerase activity analyzed by the ELISA method. PSA levels of PC patients were greater than of BPH patients (p = 0.0473). miR-130b-3p and miR-375 levels were significantly lower in pre-operative specimens of PC patients according to BPH (p = 0,0362, p = 0.0168, respectively). Similarly, post-operative miR-375 levels were lower in PC patients than in BPH patients (p = 0.1866). BPH patients had shorter RTLs than PC patients in both pre- (p=0.0438) and post-operative (p=0.0297) specimens. Telomerase activity was higher in PC patients than BPH(p = 0.0129). Interestingly, telomerase activity was further increased after surgery (p = 0.0003). We aim to identify the levels of miR-130b-3p and miR-375 expression and their relationship with telomerase activity in PC patients. Our data suggest that miRNAs and telomere length (TL) with telomerase activity may play a role in regulating prostate tumorgenesis and may be used as biomarkers for PC diagnosis.
dc.identifier.doi10.1080/15257770.2024.2334896
dc.identifier.eissn1532-2335
dc.identifier.endpage147
dc.identifier.issn1525-7770
dc.identifier.issue2
dc.identifier.pmid38593055
dc.identifier.scopus2-s2.0-85190437266
dc.identifier.startpage136
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/bayburt/11539
dc.identifier.volume44
dc.identifier.wosWOS:001200456500001
dc.language.isoen
dc.publisherTaylor and Francis Ltd.
dc.relation.ispartofNucleosides, Nucleotides and Nucleic Acids
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectmiR-130b-3p
dc.subjectmiR-375
dc.subjectProstate cancer
dc.subjecttelomerase activity
dc.subjecttelomere length
dc.subject.classificationBiochemistry & Molecular Biology
dc.subject.otherAged
dc.subject.otherHumans
dc.subject.otherMale
dc.subject.otherMicroRNAs
dc.subject.otherMiddle Aged
dc.subject.otherProstatic Hyperplasia
dc.subject.otherProstatic Neoplasms
dc.subject.otherTelomerase
dc.subject.otherTelomere
dc.subject.otherTelomere Homeostasis
dc.subject.otherbiological marker
dc.subject.othercomplementary DNA
dc.subject.othergenomic DNA
dc.subject.othermicroRNA
dc.subject.othermicroRNA 130b 3p
dc.subject.othermicroRNA 375
dc.subject.otherprostate specific antigen
dc.subject.otherunclassified drug
dc.subject.otherMIRN130 microRNA, human
dc.subject.otherMIRN375 microRNA, human
dc.subject.otheradult
dc.subject.otherArticle
dc.subject.othercancer diagnosis
dc.subject.othercancer staging
dc.subject.othercentrifugation
dc.subject.otherclinical article
dc.subject.othercontrolled study
dc.subject.otherDNA isolation
dc.subject.otherDNA synthesis
dc.subject.otherenzyme activity
dc.subject.otherenzyme linked immunosorbent assay
dc.subject.othergene expression level
dc.subject.othergene number
dc.subject.otherGleason score
dc.subject.otherhuman
dc.subject.otherhuman tissue
dc.subject.otherpathogenesis
dc.subject.otherprostate cancer
dc.subject.otherprostate hypertrophy
dc.subject.otherprotein blood level
dc.subject.otherradical prostatectomy
dc.subject.otherreal time polymerase chain reaction
dc.subject.otherRNA extraction
dc.subject.othertelomere length
dc.subject.otherblood
dc.subject.othergenetics
dc.subject.othermetabolism
dc.subject.otherpathology
dc.subject.otherprostate tumor
dc.titleEvaluation of miR-130b-3p and miR-375 levels and telomere length with telomerase activity in prostate cancer
dc.typeArticle
rdl.citation.openalex0
rdl.citation.scopus0
rdl.citation.wos0
rdl.departmentDepartment of Physiology, Adiyaman University Faculty of Medicine, Adiyaman, Turkey
rdl.departmentHealth Services Vocational School, Bayburt University, Bayburt, Turkey
rdl.departmentDepartment of Urology, Istanbul Aydin University, Faculty of Medicine, Istanbul, Turkey
rdl.departmentDepartment of Urology, Eskişehir Osmangazi University, Faculty of Medicine, Eskişehir, Turkey
rdl.departmentDepartment of Physiology, EskişehirOsmangazi University, Faculty of Medicine, Eskişehir, Turkey
rdl.oa.statusgreen
rdl.oa.statuspreprint
rdl.oa.urlhttps://hdl.handle.net/11552/7803
rdl.scopus.quartileQ3
rdl.sdgSDG03
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)